VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call

NEXT STORY
Japan Cell Therapy Transaction Yields $3MM
PREV STORY
AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Journal of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study of Migalastat for Patients with Fabry Disease

CRANBURY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology ...

author_avatar
NASDAQ Market News

Silicon Valley TMS Now Offering Cutting Edge Mental Health Technology for Obsessive-Compulsive Disorder (OCD) in Northern California

author_avatar
NASDAQ Market News

Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis

OXNARD, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Oak Therapeutics, a subsidiary of CURE ...

author_avatar
NASDAQ Market News